EASTONBIOPHARMACEUTICALS(SH:688513) Ge Long Hui A P P·2025-09-23 10:12Group 1 - The company aims to enhance its strategic development by increasing its stake in Shanghai Chaoyang from 30.68% to 51.48%, thereby gaining control over the company [1][2] - The strategic investment will strengthen the company's research and development capabilities in the innovative drug sector, facilitating a shift from generic drugs to innovation-driven growth [1] - The investment will leverage Shanghai Chaoyang's targeted protein degradation technology platform to expand into significant therapeutic areas such as hematologic malignancies and autoimmune diseases [1] Group 2 - The company plans to invest a total of 85.71 million yuan in Shanghai Chaoyang, with the capital increase price set at 2.27 yuan per registered capital [2] - Following the capital increase, Shanghai Chaoyang's registered capital will rise from 88 million yuan to 125.71 million yuan, making it a wholly-owned subsidiary of the company [2] - Other shareholders of Shanghai Chaoyang have waived their preemptive rights for this capital increase [2]